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Colchicine Acutely Suppresses Local Cardiac Production of
Inﬂammatory Cytokines in Patients With an Acute Coronary
Syndrome
Gonzalo J. Martınez, MD;* Stacy Robertson, PhD;* Jennifer Barraclough, MBBS; Qiong Xia, BSc; Ziad Mallat, MD, PhD;
Christina Bursill, PhD; David S. Celermajer, MBBS, PhD, DSc; Sanjay Patel, MBBS, PhD
Background-—Interleukin (IL)-1b, IL-18, and downstream IL-6 are key inﬂammatory cytokines in the pathogenesis of coronary
artery disease. Colchicine is believed to block the NLRP3 inﬂammasome, a cytosolic complex responsible for the production of
IL-1b and IL-18. In vivo effects of colchicine on cardiac cytokine release have not been previously studied. This study aimed to (1)
assess the local cardiac production of inﬂammatory cytokines in patients with acute coronary syndromes (ACS), stable coronary
artery disease and in controls; and (2) determine whether acute administration of colchicine inhibits their production.
Methods and Results-—Forty ACS patients, 33 with stable coronary artery disease, and 10 controls, were included. ACS and stable
coronary artery disease patients were randomized to oral colchicine treatment (1 mg followed by 0.5 mg 1 hour later) or no
colchicine, 6 to 24 hours prior to cardiac catheterization. Blood samples from the coronary sinus, aortic root (arterial), and lower
right atrium (venous) were collected and tested for IL-1b, IL-18, and IL-6 using ELISA. In ACS patients, coronary sinus levels of
IL-1b, IL-18, and IL-6 were signiﬁcantly higher than arterial and venous levels (P=0.017, <0.001 and <0.001, respectively).
Transcoronary (coronary sinus-arterial) gradients for IL-1b, IL-18, and IL-6 were highest in ACS patients and lowest in controls
(P=0.077, 0.033, and 0.014, respectively). Colchicine administration signiﬁcantly reduced transcoronary gradients of all 3
cytokines in ACS patients by 40% to 88% (P=0.028, 0.032, and 0.032, for IL-1b, IL-18, and IL-6, respectively).
Conclusions-—ACS patients exhibit increased local cardiac production of inﬂammatory cytokines. Short-term colchicine
administration rapidly and signiﬁcantly reduces levels of these cytokines. ( J Am Heart Assoc. 2015;4:e002128 doi: 10.1161/
JAHA.115.002128)
Key Words: atherosclerosis • coronary sinus sampling • cytokines • inﬂammation
M ultiple pathways are responsible for inﬂammationin acute coronary syndromes.1,2 Monocytes/macro-
phages are key effector cells in atherosclerosis-associated
inﬂammation, leading to both plaque progression and
instability.3 Moreover, it has recently been shown that the
nucleotide-binding oligomerization domain-like receptors, pyrin
domain-containing 3 (NLRP3) inﬂammasome—a cytosolic pro-
tein complex that serves as sensor of either pathogen invasion or
cellular stress4–6—promotes caspase-1 activation, and there-
fore the production of active interleukin (IL)-1b and IL-18, key
mediators in atherosclerotic plaque development, progression,
and destabilization.7,8 Furthermore, this inﬂammatory milieu
leads to increased levels of IL-6 and C-reactive protein (CRP),
which signiﬁcantly correlate with the incidence of future
cardiovascular events in patients with atherosclerosis.9,10
Colchicine is a simple, inexpensive, yet potent anti-inﬂam-
matory drug that is approved for the management of patients
with acute gout, and other inﬂammatory conditions such as
pericarditis.11,12 Purported mechanisms of action in leuko-
cytes include its ability to suppress NLRP3 inﬂammasome13
through disruption of microtubule formation,14 impairing
mitochondrial colocalization of the inﬂammasome proteins
and thus inﬂammasome activation and cytokine production.
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Here, we hypothesize that (1) local coronary production of
the inﬂammasome-speciﬁc cytokines IL-1b and IL-18 together
with IL-6, a key downstream inﬂammatory cytokine, will be
higher in patients with acute coronary syndromes (ACS) than
in patients with stable coronary artery disease (CAD) or
subjects without signiﬁcant CAD; and (2) administration of
colchicine to ACS patients will result in lower transcoronary
release of these cytokines.
Methods
Consecutive adult patients (>21 years old) with a clinical
indication for cardiac catheterization at Royal Prince Alfred
Hospital (Sydney, Australia) were invited to participate in the
study. According to their clinical presentation they were
divided in 3 groups:
1. ACS—patients with recent-onset chest pain, associated
with ST segment and/or T wave ECG changes and/or
positive cardiac enzymes (creatine kinase or troponin T).
This group included patients with unstable angina as well
as non-ST-segment elevation myocardial infarction (as per
American College of Cardiology/American Heart Associa-
tion 2007 guidelines15).
2. Stable CAD—This group included symptomatic patients
with stable angina (chest pain on exertion for >3 months)
and asymptomatic patients with positive functional tests
and obstructive coronary disease (deﬁned as diameter
stenosis >50%).
3. Controls—patients found to have no signiﬁcant coronary
disease (absence of angiographic evidence of any stenosis
>20%).
Patients included in the ACS and stable CAD groups were
randomized in a 1:1 fashion to receive either colchicine
(1 mg, followed by 0.5 mg 1 hour later) or no colchicine
therapy, 6 to 24 hours prior to coronary angiography. This
dose regimen was chosen in accordance with current
recommendations for the treatment of acute gout.11
Patients with the following characteristics were prospec-
tively excluded from the study:
1. Patients with >50% stenosis in the left main coronary
artery
2. ST elevation myocardial infarction
3. Cardiogenic shock or hemodynamic instability
4. Known hypersensitivity to colchicine
5. Moderate renal dysfunction (creatinine clearance <45 mL/
min) or hepatic dysfunction (alanine aminotransferase 1.59
upper limit of normal range)
6. Thrombocytopenia or leukopenia
7. Pregnant or lactating women and women at risk of
pregnancy
8. Patients taking moderate-strong CYP3A4 inhibitors
9. Patients already taking colchicine
10. Those with evidence of active infection or inﬂammatory
conditions that might be associated with markedly
elevated CRP levels in the blood (eg, active rheumatoid
arthritis) and those taking other anti-inﬂammatory thera-
pies (eg, corticosteroids)
Demographic and clinical data were recorded. The local
Ethics Review Committee approved the study protocol and all
patients gave written informed consent before participating.
Blood Sampling
A standard coronary angiogram was performed in all patients.
Subsequently, right femoral vein access was obtained with a
5F sheath and a 5F Simmons catheter was advanced into the
right atrium. Our technique to cannulate the coronary sinus
(CS) ostium has been detailed previously.16 This technique
allows for a safe and reliable sampling of the CS blood.
Twenty milliliters of blood was drawn from the CS, lower right
atrium–inferior vena cava junction (venous), and ascending
aorta (arterial). For those patients proceeding to clinically
indicated percutaneous coronary intervention, blood sampling
was performed immediately after the diagnostic angiogram
but before the intervention. All patients received 2500 units of
heparin prior to CS sampling; if percutaneous coronary
intervention was performed, patients received additional
heparin aiming for an activated clotting time >250.
Detection of IL-1b, IL-18, and IL-6 in Plasma
Blood samples were placed into vacuum vials containing
EDTA. Samples were immediately centrifuged and plasma was
collected and stored at 80°C. Plasma IL-1b, IL-18, and IL-6
concentrations were measured by highly sensitive ELISA using
the speciﬁc antibodies (IL-1b and IL-6: R&D Systems,
Minneapolis, MN; IL-18: Medical and Biological Laboratories,
Woburn, MA). The protocols used were those recommended
by the antisera suppliers. For IL-1b, IL-18, and IL-6 the
minimum detection limit were 1, 12.5, and 0.70 pg/mL,
respectively, and inter- and intra-assay coefﬁcient of vari-
ances were <10% for each assay.
Statistical Analysis
Continuous variables are reported as mean SD or SEM and
categorical variables as number (percentage). Normal distri-
bution was tested by the Shapiro–Wilk test. Differences in
continuous variables (eg, IL-1b concentration) were tested via
the use of an independent-samples t test or nonparametric
test for non-normally distributed data (Mann–Whitney U test),
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while proportional differences in categorical variables (eg,
patient did or did not have hypertension) were tested via the
use of Fisher’s Exact Test. Multiple, nonpaired samples were
tested with 1-way ANOVA or Kruskal–Wallis test and multiple
paired samples with Friedman test. All tests were 2-tailed with
the acceptable type 1 error set at P<0.05. Statistical analysis
was performed with SPSS 21 software (IBM, Armonk, NY) and
ﬁgures were created with GraphPad Prism 6.0 (GraphPad
Software, La Jolla, CA).
Results
From September 2013 to August 2014, 83 patients were
included in the study. Of these, 40 patients presented with an
ACS, 33 patients with stable CAD, and 10 patients had no
angiographically signiﬁcant CAD and served as controls.
Within the ACS group, 21 patients were randomized to
colchicine treatment and 19 individuals to “no treatment.” In
the stable CAD group, 7 nontreated patients were initially
studied, while sampling techniques were being optimized,
after which 26 patients were randomized to colchicine or no
therapy. The initial 7 patients were included in the ﬁnal
analysis, with 13 colchicine-treated patients and 20 untreated
patients.
Baseline Characteristics
Baseline characteristics for ACS, stable CAD, and control
groups and characteristics by colchicine treatment random-
ization groups are presented in Tables 1 and 2. Groups were
comparable for most risk factors, treatments, and blood test
results. However, within the ACS group, those allocated to
colchicine treatment were more likely to have been diabetic
(P=0.04) and therefore more likely to be taking oral
hypoglycemics (P=0.02). In the stable CAD group there was
a trend to more diabetics in the colchicine-treated group,
although this was not statistically signiﬁcant (P=0.06).
Interleukin-1b
In ACS colchicine-na€ıve patients, CS IL-1b levels were signif-
icantly higher than arterial and venous levels (13.42, 9.68, and
9.49 pg/mL, for CS, arterial and venous, respectively;
P=0.017) (Figure 1), whereas in stable CAD patients, IL-1b
levels were nonsigniﬁcantly higher in the CS versus artery and
vein (9.29, 8.42, and 8.55 pg/mL, for CS, arterial and venous,
respectively; P=0.058) (Figure 1A). In the control group, there
was no difference in IL-1b concentrations between the 3
sampling sites (7.88, 7.93, and 7.75 pg/mL, for CS, arterial
and venous, respectively; P=1). There appeared to be a
Table 1. Baseline Characteristics for ACS, Stable CAD, and Control Groups
ACS Stable CAD Controls P Value
Number 40 33 10 —
Age, y—mean (SD) 64.5 (10.2) 61.1 (10.3) 61.3 (6.7) 0.32
Female (%) 3 (8) 3 (9) 3 (30) 0.29
Diabetes mellitus (%) 13 (33) 13 (39) 2 (20) 0.42
Hypertension (%) 27 (68) 19 (58) 3 (30) 0.06
Dyslipidemia (%) 27 (68) 23 (70) 5 (50) 0.68
Current smoker (%) 10 (25) 6 (18) 3 (30) 0.70
Previous MI (%) 7 (18) 10 (30) 1 (10) 0.28
Previous PCI (%) 7 (18) 9 (27) 0 (0) 0.17
Previous CABG (%) 1 (3) 6 (18) 0 (0) 0.05
Medications
Aspirin (%) 40 (100) 33 (100) 8 (80) 0.134
Thienopyridines (%) 38 (95) 26 (79) 6 (60) 0.017
b-Blockers (%) 30 (75) 17 (52) 3 (30) 0.023
ACE-I/ARA-2 (%) 25 (63) 20 (61) 4 (40) 0.331
Statins (%) 36 (90) 27 (82) 7 (70) 0.115
Hypoglycemics (%) 12 (30) 12 (36) 1 (10) 0.231
Insulin (%) 3 (8) 2 (6) 0 (0) 1
ACE-I indicates angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARA-2, angiotensin 2 receptor antagonist; CABG, coronary artery bypass graft surgery; MI,
myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease.
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relationship between IL-1b CS—arterial or transcoronary
gradient (a measure of intracardiac production) and clinical
category, with the highest gradients found in ACS patients, and
lowest in control patients; however, this was not statistically
signiﬁcant (P=0.077) (Figure 2A). Notably, the CS-arterial (A)
gradient from ACS but not stable CAD patients was signiﬁcantly
higher compared to CS-A gradient from control patients
(P=0.028). On the other hand, no difference in the venous
concentration of IL-1b was seen between groups (P=0.611).
Interleukin-18
In both ACS and stable CAD colchicine-na€ıve groups, CS levels
of IL-18 were signiﬁcantly higher than in the aorta or peripheral
vein (ACS: 325.82, 287.64, and 285.11; stable CAD: 346.50,
318.43, and 312.82 pg/mL, for CS, arterial and venous,
respectively; P<0.001 for both comparisons) (Figure 1B),
whereas no difference was found in the control group
(280.77, 271.30, and 272.31 pg/mL, for CS, arterial and
venous, respectively; P=0.174). In similar fashion to IL-1b,
there was a signiﬁcant relationship between the CS-A gradient
and clinical presentation, with highest transcoronary gradients
found in ACS patient, and lowest gradients in controls
(P=0.033). However, peripheral venous concentrations of this
cytokine did not change across groups (Figure 2B).
Interleukin-6
In patients with both ACS and stable CAD, there were
signiﬁcantly higher concentrations of this cytokine in the CS
(70.13, 21.47, 22.96 pg/mL, for CS, arterial and venous in
ACS patients, respectively; P<0.001; 6.64, 4.44, 3.47 pg/mL,
for CS, arterial and venous in stable CAD patients; P<0.001)
(Figure 1C). Both transcoronary concentration gradients and
venous concentrations were markedly higher in ACS patients
versus stable CAD and control groups (P=0.014) (Figure 2C).
Of note, no differences in IL-1b, IL-18, or IL-6 CS or peripheral
blood levels were seen between diabetic and nondiabetic
patients in both stable and unstable CAD patient groups.
Effect of Colchicine Treatment on IL-1b, IL-18,
and IL-6 Levels
The results for CS and CS-A gradient plasma concentrations
of IL-1b, IL-18, and IL-6 in ACS and stable CAD patients
according to colchicine treatment are summarized in Table 3.
Table 2. Baseline Characteristics for ACS and Stable CAD Groups, by Colchicine Administration
ACS (n=40) Stable CAD (n=33)
Colchicine No Colchicine P Value* Colchicine No Colchicine P Value†
Number 21 19 — 13 20 —
Age, y—mean (SD) 65.0 (8.9) 64.0 (11.7) 0.76 59.9 (11.3) 61.8 (10.0) 0.63
Female (%) 3 (14) 0 (0) 0.23 1 (8) 2 (10) 1
Diabetes mellitus (%) 10 (48) 3 (16) 0.04 8 (62) 5 (25) 0.06
Hypertension (%) 13 (62) 14 (74) 0.51 8 (62) 11 (55) 0.71
Dyslipidemia (%) 13 (62) 14 (74) 0.51 11 (85) 12 (60) 1
Current smoker (%) 6 (29) 4 (21) 0.72 1 (8) 5 (25) 0.63
Previous MI (%) 2 (10) 5 (26) 0.23 6 (46) 4 (20) 0.23
Previous PCI (%) 3 (14) 4 (21) 0.69 1 (8) 8 (40) 0.19
Previous CABG (%) 0 (0) 1 (5) 0.48 2 (15) 4 (20) 1
Medications
Aspirin (%) 21 (100) 19 (100) — 13 (100) 20 (100) —
Thienopyridines (%) 20 (95) 18 (95) 1 11 (85) 15 (75) 1
b-Blockers (%) 16 (76) 14 (74) 1 7 (54) 10 (50) 1
ACE-I/ARA-2 (%) 11 (52) 14 (74) 0.20 9 (69) 11 (55) 0.44
Statins (%) 19 (91) 17 (89) 1 11 (85) 16 (80) 1
Hypoglycemics (%) 10 (48) 2 (11) 0.02 7 (54) 5 (25) 0.24
Insulin (%) 1 (5) 2 (11) 0.59 1 (8) 1 (5) 1
ACE-I indicates angiotensin-converting enzyme inhibitors; ACS, acute coronary syndrome; ARA-2, angiotensin 2 receptor antagonist; CABG, coronary artery bypass graft surgery; MI,
myocardial infarction; PCI, percutaneous coronary intervention; CAD, coronary artery disease.
*Difference between colchicine vs. no colchicine within ACS group.
†Difference between colchicine vs. no colchicine within stable CAD group.
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Colchicine treatment reduced absolute CS IL-1b concentra-
tion as well as the CS-A gradient in patients with ACS
(P=0.024 and 0.028, respectively) (Figure 3A). These results
A
B
C
Figure 1. Venous, arterial, and coronary sinus (A) IL-1b,
(B) IL-18, and (C) IL-6 concentrations in colchicine-na€ıve
ACS and stable CAD patients. Results expressed as mean
and SEM. A indicates arterial; ACS, acute coronary
syndrome; CAD, coronary artery disease; CS, coronary
sinus; IL, interleukin; V, venous.
A
B
C
Figure 2. Transcoronary gradients and venous concen-
trations of (A) IL-1b, (B) IL-18, and (C) IL-6 according to
clinical presentation. Results expressed as mean and SEM.
A indicates arterial; ACS, acute coronary syndrome; CS,
coronary sinus; IL, interleukin; V, venous.
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represented a 33% reduction in the CS plasma concentration
of IL-1b with colchicine treatment in ACS patients, in contrast
with only a 6% difference in patients with stable CAD
(P<0.001 for the difference in effect between ACS and stable
CAD groups). For IL-18, colchicine treatment similarly resulted
in a signiﬁcant reduction in CS-A gradient, again only in the
ACS group (Figure 3B). Finally, colchicine therapy in ACS
patients resulted in an 88% lower CS concentration of IL-6
(12.79 versus 77.00 pg/mL) and an 83% lower CS-A gradient
(6.02 versus 53.90 pg/mL) versus untreated patients
(P=0.004 and 0.032, respectively) (Figure 3C). In stable
CAD patients, colchicine treatment was associated with a
very low IL-6 transcoronary gradient; however, this was not
statistically signiﬁcant (0.29 pg/mL for colchicine-treated
versus 2.20 pg/mL for colchicine na€ıve versus 1.01 pg/mL
for controls, P=0.057). In contrast to the inﬂammasome-
speciﬁc cytokines, IL-6 venous levels did signiﬁcantly change
with colchicine administration (22.86 versus 5.96 versus
2.32 pg/mL for ACS untreated, ACS treated, and control
patients, P=0.011). As there were signiﬁcantly more diabetic
patients in the ACS colchicine group than the ACS non-
colchicine group, a sensitivity analysis with adjustment for
diabetes and oral hypoglycemic agents was performed. This
yielded similar signiﬁcant differences in cytokine levels
between groups. Groups were otherwise well matched with
respect to other baseline characteristics.
Discussion
There are 3 main ﬁndings in this study. First, the transcoro-
nary gradients of all 3 inﬂammatory cytokines studied strongly
correlated with disease activity, with the highest gradients
found in ACS patients, and lowest in patients without any
obstructive CAD. Second, venous plasma concentrations of
the inﬂammasome-speciﬁc cytokines, IL-1b and IL-18, do not
reliably identify increased transcoronary production. Finally,
short-term colchicine treatment of ACS patients was associ-
ated with signiﬁcantly lower transcoronary release of IL-1b
and IL-18, as well as IL-6, a key downstream pro-inﬂammatory
cytokine strongly associated with atherosclerosis-associated
inﬂammation (Figure 4).
Increased Transcoronary Production of IL-1b and
IL-18 Is Found in ACS Patients
IL-1b is a key inﬂammatory cytokine and has been identiﬁed
in multiple disease states.17 It exerts pro-inﬂammatory
(neutrophil recruitment, increase in IL-6 and tumor necrosis
factor-a, stimulation of phagocytosis, increase of intracellular
adhesion molecule-1 and vascular permeability, CD4 and B-
cell activation) and prothrombogenic effects (increase in
plasminogen activator inhibitor 1 and ﬁbrinogen), by binding
to the IL-1 type 1 receptor.18 IL-1b might also be directly
involved in plaque destabilization by the stimulation of matrix
metalloproteinases.19 Abundant evidence supports the par-
ticipation of IL-1b in atherothrombosis, although most of this
comes from studies in animal models or ex vivo human
samples. IL-1b or IL-1 type 1 receptor-deﬁcient mice are
characterized by reduced atherosclerotic lesions,20,21 and IL-
1b exposure in Apo E/ mice resulted in enhanced aortic
plaque development.7 In humans, a study in explanted hearts
demonstrated increased IL-1b levels in arteries with coronary
disease.22 Our results show that there is higher local cardiac
production of IL-1b in patients with acute coronary events. It
remains unclear, however, whether IL-1b production is
derived from macrophages in acute plaques, from macro-
phages in the infarcted myocardium, or both. However, given
that there was no statistically signiﬁcant difference in IL-1b
levels in patients with and without troponin elevations
(P=0.308), this strongly suggests a vascular rather than a
Table 3. Coronary Sinus and Transcoronary Gradient Plasma Concentrations of IL-1b and IL-18, by Colchicine Administration
ACS
Controls P Value*
Stable CAD
Controls P Value†Colchicine No Colchicine Colchicine No Colchicine
Number 21 19 10 — 13 20 10 —
CS IL-1b 8.95 (0.26) 13.42 (2.59) 7.88 (0.18) 0.024 8.54 (0.38) 9.29 (0.43) 7.88 (0.18) 0.074
Gradient IL-1b 0.87 (0.32) 3.75 (1.87) 0.05 (0.17) 0.028 0.53 (0.41) 0.87 (0.38) 0.05 (0.17) 0.313
CS IL-18 301.42 (18.17) 325.88 (24.49) 280.66 (30.25) 0.239 349.54 (41.21) 346.50 (40.46) 280.66 (30.25) 0.434
Gradient IL-18 22.85 (6.50) 38.20 (6.25) 9.33 (9.04) 0.032 32.42 (4.43) 28.14 (6.10) 9.33 (9.04) 0.077
CS IL-6 12.79 (2.97) 77.00 (26.28) 4.31 (0.42) 0.004 4.75 (0.86) 6.64 (1.07) 4.31 (0.42) 0.617
Gradient IL-16 6.02 (2.47) 53.90 (23.07) 1.01 (0.36) 0.032 0.29 (0.47) 2.20 (0.85) 1.01 (0.36) 0.057
All data: mean (SEM) (pg/mL). ACS indicates acute coronary syndrome; CS, coronary sinus; IL, interleukin; CAD, coronary artery disease.
*Difference between ACS colchicine vs. ACS no colchicine vs. controls.
†Difference between stable CAD colchicine vs. stable CAD no colchicine vs. controls.
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myocardial origin of this cytokine. Also, it has been suggested
that statin type may inﬂuence inﬂammasome activation, with
rosuvastatin having a greater inhibitory effect than atorvas-
tatin.23 In our study, however, no differences were seen,
irrespective of statin type, with 40% of statin-treated
patients on rosuvastatin and the other 60% on atorvastatin.
As the majority of these patients were on dual antiplatelet
inhibition and statins, these ﬁndings also suggest ongoing
inﬂammation in ACS patients despite best available therapy.
Accordingly, further inhibition of the IL-1b pathway seems
attractive as a potential treatment for the acute period of
unstable coronary disease. Indeed, the CANTOS trial is
currently testing the hypothesis that canakinumab, a speciﬁc
IL-1b human monoclonal antibody, would reduce events in
stable but persistently inﬂamed post–myocardial infarction
patients.24 In contrast to canakinumab, colchicine also has
inhibitory effects on neutrophils, which also contribute to
plaque progression and plaque destabilization;25 however, the
clinical beneﬁts of colchicine versus canakinumab are still to
be determined.
IL-18 has also been implicated in CAD pathogene-
sis.8,26,27 Systemic concentrations of IL-18 have been
shown to predict future cardiovascular events in patients
with both stable and unstable symptoms, and its prognostic
value is additive to other recognized inﬂammatory markers,
such as C-reactive protein and IL-6.28 Moreover, variations
of the IL18 gene inﬂuence outcomes in patients with CAD,
suggesting a causal role for IL18 in the complications of
atherosclerosis.29 Our data suggest increased local produc-
tion of IL-18 in patients with CAD, in a similar fashion to
IL-1b, in agreement with a common inﬂammasome-medi-
ated pathway underlying their production. The results are
also consistent with the signiﬁcant association between
caspase-1 levels and cardiovascular events in CAD
patients.30 Accordingly, inhibition of this cytokine could
also be attractive; however, to our knowledge, no speciﬁc
drug is currently under testing for this purpose.
IL-6 Correlates With Levels of Inﬂammasome-
Speciﬁc Cytokines
Increased cardiac production of IL-6 in patients with acute
myocardial infarction has previously been demonstrated.31
Moreover, IL-6 levels in venous blood are strongly associ-
ated with both disease activity in ACS,32 as well as being
predictive of future coronary events in patients with stable
disease.33,34 Similarly, in our study, both transcoronary and
venous levels of IL-6 correlated signiﬁcantly with disease
activity, in parallel with the transcoronary levels of the
inﬂammasome-speciﬁc cytokines, IL-1b and IL-18. As IL-1b
is known to play a pivotal role in IL-6 production, these
data suggest a plausible link between increased local
production of inﬂammasome-speciﬁc inﬂammatory cytoki-
nes, increased plaque vulnerability, and unstable coronary
events.
A
B
C
Figure 3. (A) IL-1b, (B) IL-18, and (C) IL-6 transcoronary
gradients in ACS patients and controls, according to colchicine
treatment. Results expressed as mean and SEM. ACS indicates
acute coronary syndrome; CS-A gradient, coronary sinus–arterial
gradient; IL, interleukin.
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Acute Colchicine Treatment Suppresses the
Intracardiac Synthesis of IL-1b, IL-18, and IL-6
Colchicine administration in patients with unstable CAD within
the 24 hours prior to cardiac catheterization signiﬁcantly
reduced local synthesis of IL-1b, IL-18, and IL-6, as well as
venous concentrations of IL-6 (Figure 4). The acute suppres-
sion of these pro-inﬂammatory cytokines in ACS patients
potentially has important therapeutic implications. ACS are
characterized by widespread vascular inﬂammation,35 affect-
ing not only the culprit lesion but also multiple coronary
segments, thus potentially promoting plaque rupture and
erosion and subsequent events.36 Acute inhibition of a
number of key effectors in this inﬂammatory cascade with
colchicine—an oral and inexpensive drug—could therefore
reduce the incidence of new coronary events, which are
common post-ACS,37 by stabilizing both culprit and noncul-
prit lesions. Indeed, values as high as 15% of new cardio-
vascular events on 3-year follow-up have been described in
recent trials.38 Moreover, IL-6 has been strongly linked with
increased risk of cardiovascular events in large epidemiolog-
ical studies.34 Our study demonstrated a marked reduction in
local IL-6 production as well as venous levels with colchicine,
suggesting a potential role for colchicine in reducing this
risk.
A recently published study showed that a subcutaneous
IL-1 receptor antagonist (Anakinra) administered daily for
14 days was associated with a signiﬁcant reduction in CRP
and IL-6 compared to placebo.39 Although both CRP and IL-6
have been shown to predict events in patients with ACS,10,40
Anakinra was associated with an increase in clinical events at
1-year follow-up. A possible explanation is the rebound in the
inﬂammatory response (as revealed by a signiﬁcant increase
of high-sensitivity CRP levels at day 30) after a too-short
treatment (14 days) with anakinra. Thus, a more prolonged
inhibition of the IL-1 pathway or a broader inhibition of the
inﬂammatory response using an anti-inﬂammasome agent,
such as colchicine, could have clinical potential. Encourag-
ingly, in this regard, the LoDoCo trial showed signiﬁcant
beneﬁt of long-term colchicine treatment in patients with
stable CAD, mainly due to a reduced number of acute events
during follow-up (that is, predominantly by preventing plaque
destabilization).41 The ongoing Cardiovascular Inﬂammation
Reduction Trial (CIRT), testing the effect of methotrexate on
cardiovascular outcomes, may also support the use of anti-
inﬂammatories to prevent secondary cardiovascular events.42
It is possible based on the results of the current study that
suppression of inﬂammasome-related cytokines may play a
key role in effects of colchicine on acute plaque instability and
the reduction of clinical events. This clearly requires further
assessment; our current study was powered to examine a
reduction in transcoronary cytokine release but not to assess
clinical event rates.
The mechanisms by which colchicine inhibits the produc-
tion of these cytokines are not completely understood. It has
been suggested that colchicine might block crystal
endocytosis and posterior stimulation of the inﬂammasome
complex.43 Colchicine might have a transcriptional effect by
blocking the MEFV gene, thereby inhibiting the production of
the inﬂammasome complex proteins.44 Also, colchicine has
been shown to prevent mobilization of a key protein
in inﬂammasome complex assembly, known as apoptosis-
associated speck-like protein containing caspase and activa-
tion recruitment domain (CARD) (ASC) from the mitochondria
to the endoplasmic reticulum and thus prevents its colocal-
ization with the rest of the inﬂammasome complex.14 It is
Figure 4. Effect of short-term colchicine on local cardiac and systemic inﬂammation in
acute coronary syndrome patients. IL indicates interleukin.
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plausible that colchicine might exert its effects upon the
inﬂammasome complex in more than 1 way. For example, it
might rapidly inhibit the inﬂammasome complex assembly,
hence exerting an acute effect, as demonstrated in the
present study. It may also have a transcriptional effect,
inhibiting the production of IL-1b and IL-18, a mechanism that
might take longer to act and be related to more long-term
exposure to the drug.
Limitations
Study limitations include a relatively small sample size. Also,
although our study demonstrates increased cardiac produc-
tion of inﬂammasome-associated cytokines in ACS, we
cannot determine whether changes in cytokines contribute
to ongoing coronary inﬂammation or are simply released as a
consequence of plaque rupture and erosion. Moreover,
mechanisms of inﬂammasome activation in this setting and
the subacute/chronic time course of cytokine release require
further exploration. Our study was designed to test the
effects of short-term colchicine administration on the local
cardiac production of cytokines. However, long-term use of
this drug and its possible side effects were not evaluated.
Finally, patients were not followed with respect to clinical
outcomes.
Conclusions
In the present study, we have demonstrated increased
intracardiac production of the inﬂammasome speciﬁc cytoki-
nes IL-1b, IL-18 and downstream IL-6 in patients presenting
with an ACS.
Furthermore, acute colchicine administration is associated
with a signiﬁcant reduction in the transcoronary production of
these cytokines in patients with ACS. These data suggest a
possible therapeutic role for colchicine in acutely suppressing
atherosclerosis-associated inﬂammation.
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